RI-AG03
RI-AG03 is an orally active and a BBB-penetrable Tau aggregation peptide inhibitor. RI-AG03 inhibits Tau aggregation and improves associated neurodegeneration and behavioral phenotypes in both in vivo and in vitro models. RI-AG03 can be used in the study of tauopathies such as Alzheimer's disease[1][2].
Product Specifications
UNSPSC
12352209
Target
Tau Protein
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Smiles
O=C(N[C@H](CCCNC(N)=N)C(N[C@H](CCCNC(N)=N)C(N[C@H](CCCNC(N)=N)C(N[C@H](CCCNC(N)=N)C(N[C@H](CCCNC(N)=N)C(N[C@H](CCCNC(N)=N)C(N[C@H](CCCNC(N)=N)C(NCC(N1[C@H](CCC1)C(N[C@H](CCCCN)C(N[C@H](CC2=CC=C(C=C2)O)C(N[C@H](CCCCNC(C)=O)C(N[C@H]([C@H](C)CC)C(N[C@H](CCC(N)=O)C(N[C@H](C(C)C)C(NCC(N[C@H](CCCNC(N)=N)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@@H](CCCNC(N)=N)NC(C)=O
Molecular Formula
C104H189N49O22
Molecular Weight
2477.93
References & Citations
[1]Di Natale G, et al. Aβ and Tau Interact with Metal Ions, Lipid Membranes and Peptide-Based Amyloid Inhibitors: Are These Common Features Relevant in Alzheimer's Disease? Molecules. 2022 Aug 9;27 (16) :5066. |[2]Aggidis A, et al. A novel peptide-based tau aggregation inhibitor as a potential therapeutic for Alzheimer's disease and other tauopathies. Alzheimers Dement. 2024 Nov;20 (11) :7788-7804.
Shipping Conditions
Room temperature
Scientific Category
Peptides
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
